Fact based stock research
West Pharmaceutical Services (NYSE:WST)
US9553061055
West Pharmaceutical Services stock research in summary
West Pharmaceutical Services shares are more expensive than other comparable stocks. They show above average growth and are safely financed, but are poor value. We recommend evaluating whether the future of the company West Pharmaceutical Services is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.
Latest Obermatt Ranks
| Value Rank | 25 |  |
| Growth Rank | 89 |  |
| Safety Rank | 67 |  |
| Combined Rank | 70 | |
| Country | USA |
| Industry | Health Care Supplies |
| Index | D.J. US Medical Equipment, S&P MIDCAP |
| Size class | Large |
September 18, 2020. Stock data may be delayed. Login to get the most recent research.
Google: West Pharmaceutical Services
Research History: West Pharmaceutical Services
| RESEARCH HISTORY | 2017 | 2018 | 2019 | 2020 | ||||
|---|---|---|---|---|---|---|---|---|
| VALUE | ||||||||
| VALUE | 23 |
|
29 |
|
24 |
|
25 |
|
| GROWTH | ||||||||
| GROWTH | 40 |
|
58 |
|
55 |
|
89 |
|
| SAFETY | ||||||||
| SAFETY | 95 |
|
64 |
|
60 |
|
67 |
|
| COMBINED | ||||||||
| COMBINED | 76 |
|
50 |
|
45 |
|
70 |
|
Value Metrics in Detail
| VALUE METRICS | 2017 | 2018 | 2019 | 2020 | ||||
|---|---|---|---|---|---|---|---|---|
| PRICE VS. REVENUES (P/S) | ||||||||
| PRICE VS. REVENUES (P/S) | 19 |
|
23 |
|
24 |
|
18 |
|
| PRICE VS. PROFITS (P/E) | ||||||||
| PRICE VS. PROFITS (P/E) | 37 |
|
43 |
|
34 |
|
38 |
|
| PRICE VS. CAPITAL (Market-to-Book) | ||||||||
| PRICE VS. CAPITAL (Market-to-Book) | 22 |
|
12 |
|
16 |
|
10 |
|
| DIVIDEND YIELD | ||||||||
| DIVIDEND YIELD | 54 |
|
64 |
|
41 |
|
47 |
|
| CONSOLIDATED RANK: VALUE | ||||||||
| CONSOLIDATED RANK: VALUE | 23 |
|
29 |
|
24 |
|
25 |
|
Growth Metrics in Detail
| GROWTH METRICS | 2017 | 2018 | 2019 | 2020 | ||||
|---|---|---|---|---|---|---|---|---|
| REVENUE GROWTH | ||||||||
| REVENUE GROWTH | 34 |
|
61 |
|
22 |
|
72 |
|
| PROFIT GROWTH | ||||||||
| PROFIT GROWTH | 43 |
|
58 |
|
65 |
|
84 |
|
| STOCK RETURNS | ||||||||
| STOCK RETURNS | 55 |
|
54 |
|
69 |
|
82 |
|
| CONSOLIDATED RANK: GROWTH | ||||||||
| CONSOLIDATED RANK: GROWTH | 40 |
|
58 |
|
55 |
|
89 |
|
Safety Metrics in Detail
| SAFETY METRICS | 2017 | 2018 | 2019 | 2020 | ||||
|---|---|---|---|---|---|---|---|---|
| LEVERAGE | ||||||||
| LEVERAGE | 58 |
|
63 |
|
61 |
|
56 |
|
| REFINANCING | ||||||||
| REFINANCING | 28 |
|
24 |
|
20 |
|
19 |
|
| LIQUIDITY | ||||||||
| LIQUIDITY | 97 |
|
93 |
|
82 |
|
90 |
|
| CONSOLIDATED RANK: SAFETY | ||||||||
| CONSOLIDATED RANK: SAFETY | 95 |
|
64 |
|
60 |
|
67 |
|
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for West Pharmaceutical Services from September 18, 2020.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.